JCB logo
Accuri Cytometers
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 18 September 2006. doi:10.1083/jcb.1747rr3
The Rockefeller University Press, 0021-9525 $8.00
JCB, Volume 174, Number 7, 909-909
This Article
Right arrow Full Text (PDF, 890K)
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBrasseur, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by LeBrasseur, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Research Roundup

T cells told to keep rolling


AT cell coreceptor keeps T cells moving so that they are not overactivated, according to Helga Schneider, Christopher Rudd (University of Cambridge, UK), and colleagues. By not lingering too long, killer T cells might be at their most efficient.

Rudd's group recently found that this coreceptor, called CTLA-4, was needed for integrin activation. Integrins go hand-in-hand with cell migration, which the authors now show is increased by CTLA-4 engagement.

When T cells meet the right antigen-presenting cell (APC), they normally stop and interact with the APC to get activated. This stopping phase, the authors show, is limited by CTLA-4, which is found on all activated T cells and binds to ligands on the APC.

By restricting the interaction time, CTLA-4 may prevent responses to low-affinity self-antigens that cause autoimmunity. This idea is supported by the severe autoimmunity found in mice lacking CTLA-4. Rudd suspects that their T cells "park next to an APC for so long that they start accumulating signals against self-antigens."

The anti–stop signal might have been designed to make cytotoxic T cells more efficient in killing infected or cancerous cells. It might also explain why anti–CTLA-4 antibodies succeed as cancer therapies, if they act as ligand mimics. "The release of [cytotoxic] granzymes is relatively quick," says Rudd. "The T cell can kill the tumor target cell and not stick around any longer than it needs to, take off again and encounter another target." Formula

Reference:

Schneider, H., et al. 2006. Science. doi:10.1126/science.1131078.[Abstract/Free Full Text]



Nicole LeBrasseur

lebrasn{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Full Text (PDF, 890K)
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LeBrasseur, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by LeBrasseur, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents